Bispecific Antibodies Market Poised for Robust Expansion

The biotechnology landscape is undergoing a significant transformation, with bispecific antibodies (bsAbs) emerging as a groundbreaking therapeutic class in the treatment of various diseases, particularly cancers and autoimmune disorders. Unlike traditional monoclonal antibodies, which target a single antigen, bispecific antibodies can simultaneously bind to two different antigens or epitopes. This unique capability not only enhances therapeutic efficacy but also expands the potential for innovative treatment strategies. This article explores the driving forces behind the surge in bispecific antibodies demand, the market dynamics, current applications, and future trends shaping this rapidly evolving sector.